Adipotide (FTPP) AP
Adipose-vasculature targeting peptidomimetic
Peptidomimetic linking a prohibitin-binding homing sequence to a pro-apoptotic sequence, studied for selective loss of adipose vasculature.
Evidence level. Evidence comes mainly from animal or other preclinical models. About the badges
- Class
- Adipose-vasculature targeting peptidomimetic
- Category
- Fat Metabolism & Lipotropics
- Type
- Single compound
- Abbreviation
- AP
- Development and regulatory status
- Not approved; preclinical research compound
What researchers study
Adipotide (FTPP) is a peptidomimetic that links a homing sequence binding prohibitin, a protein on blood vessels supplying white fat, to a pro-apoptotic sequence. It is studied for selective loss of adipose vasculature.
Research areas
- Targeting white-fat blood supply in models
- Prohibitin-binding peptide pharmacology
- Adipose tissue turnover and insulin sensitivity in primates
- Renal tolerability of vascular-targeting peptides
Reported findings
Summaries of published results. Each one is tagged with the type of study behind it. They describe research outcomes and are not claims about any product. Why study type matters.
- primate
In obese rhesus monkeys, body weight fell about 11% and MRI abdominal fat 27% versus no change in controls
- primate
Insulin resistance improved, with monkeys receiving the peptide using about 50% less insulin, and weight began to rebound after exposure ended
- primate
Reversible, dose-dependent kidney effects were the main adverse finding
